How to think about the cannabinoid category in the twilight of FDA purgatory

August 20, 2021

1 Min Read

Watch now!

Watch Now-Green Button_ [Converted] (1).png

When it comes to regulating CBD, the FDA has prioritized pharmaceutical monopoly over public health, leaving the consuming public and honest brands to fend for themselves. And with its recent rejection of “full spectrum” New Dietary Ingredient Notifications, the Agency has only pushed its head further into the sand. Join Justin Singer, CEO & Co-Founder of Caliper Foods, for this complimentary webinar, where he’ll review how we got here, and what’s next for a category that’s waiting—and waiting—for responsible unlock.

Don’t miss out - register today! 

In this webinar, you’ll learn:

  • A history of the FDA and the cannabis industry

  • Recent FDA cannabis regulatory guidance

  • What your brand can do to prepare for the future

  • Where the industry is headed

Fran Headshot_clean.jpg
Francine Schoenwetter
Content Marketing Director, Informa Markets Health & Nutrition

Justin Singer_small.jpg

Justin Singer 
CEO & Co-Founder, Caliper Foods

Justin Singer is the CEO and co-founder of Caliper Foods, parent company to Caliper Ingredients. Prior to founding Caliper, Justin spent four years teaching innovation theory and high-growth entrepreneurship at the School of Engineering at Columbia University. He began his career as an investor with IA Ventures, a seed-stage venture capital firm in New York City. Justin holds an MBA in finance from Columbia Business School, a JD in telecommunications law from Columbia Law School and a BBA in operations management from the University of Michigan Ross School of Business.

Watch Now-Green Button_ [Converted] (1).png

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like